Variability in response to aspirin: do we understand the clinical relevance?

Abstract

Aspirin, an irreversible inhibitor of platelet prostaglandin synthase activity, is the cornerstone of therapy for acute coronary syndromes. In recent years, laboratory and clinical data have accumulated that suggest there may be significant individual variability in the response to aspirin and that the effects of aspirin therapy vary significantly over time. There is, as of yet, no cohesive explanation for this variability. The term 'aspirin resistance' has been loosely applied to situations in which the clinical or ex vivo effects of aspirin are less than expected. In this review we discuss the clinical data regarding this phenomenon and the need for prospective evaluation of aspirin non-responders.

• Authors: C L Campbell, S R Steinhubl
• Journal: Journal of thrombosis and haemostasis : JTH (J Thromb Haemost) Vol. 3 Issue 4 Pg. 665-9 (Apr 2005) ISSN: 1538-7933 [Print] England
• PMID: 15703034 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Platelet Aggregation Inhibitors
• Aspirin

Topics

• Acute Disease
• Angina, Unstable (drug therapy)
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Aspirin (therapeutic use)
• Clinical Trials as Topic
• Coronary Disease (drug therapy)
• Drug Resistance
• Humans
• Myocardial Infarction (drug therapy)
• Platelet Aggregation Inhibitors (therapeutic use)
• Time Factors
• Treatment Outcome